Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2019-04-29 Major Shareholding Noti…
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils et déclaration d'intention" (Declaration of crossing thresholds and declaration of intent) and explicitly references articles from the French Commercial Code (L. 233-7) and the AMF General Regulation. It details a shareholder (Winance) crossing ownership thresholds (5%, 10%, 15%, 20%, 25%) in GENOMIC VISION due to a capital increase and outlines their intentions regarding future control and strategy. This type of mandatory disclosure regarding changes in significant share ownership is classified as a Major Shareholding Notification.
2019-04-29 French
Inside Information / Other news releases
Share Issue/Capital Change Classification · 99% confidence The document is an announcement titled "Genomic Vision announces the drawdown of the first €1.5 million tranche within the framework of the equity financing put in place with Winance." It explicitly details the issuance of new shares corresponding to a capital increase (€1.5 million) under a previously established financing contract. This action directly relates to the company's fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (4842 chars) is substantial enough that it is not merely an RPA, but the primary announcement of the financing event itself.
2019-04-15 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Genomic Vision has drawn down the first tranche of a capital financing agreement with Winance, resulting in the issuance of new shares and an increase in capital (€1.5 M). This action directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it mentions a prospectus filed with the AMF, the core purpose of this specific document is the announcement of the capital increase itself, not the filing of the full prospectus or annual report.
2019-04-15 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is providing 'Information relative au nombre total de droits de vote et d'actions composant le capital social' and references Article 223-16 of the AMF (Autorité des marchés financiers) general regulation. It presents a table detailing the total number of shares and voting rights (gross and net) as of a specific date (31.03.2019). This type of mandatory disclosure regarding the capital structure and voting rights is typically classified as a regulatory filing or a specific capital/share update. Since the definitions include 'Share Issue/Capital Change' (SHA) and 'Major Shareholding Notification' (MRQ), I must choose the best fit. This document is a formal declaration of the total capital structure and voting rights, which is a fundamental aspect of share capital reporting. While it relates to capital, it is a specific regulatory disclosure about the total count, not a transaction (POS) or a threshold crossing notification (MRQ). Given the nature of mandatory disclosure regarding the total number of shares and voting rights, it aligns closely with general capital structure reporting. However, none of the codes perfectly capture a 'Total Voting Rights Disclosure'. Since it is a formal regulatory disclosure about the capital structure, and it is not a major shareholding notification (MRQ) which focuses on changes crossing thresholds, nor a general share issue (SHA), I will evaluate the remaining options. It is a formal regulatory filing required by the AMF. If it were a change in major shareholding, MRQ would apply. Since it is a static report of the total capital structure, it fits best under a general regulatory filing (RNS) or potentially a capital update (CAP). Given the specific nature of reporting total voting rights under AMF rules, and the lack of a dedicated code, RNS (Regulatory Filings) is the most appropriate fallback for mandatory, non-standard disclosures. However, since it is fundamentally about the composition of the capital, SHA (Share Issue/Capital Change) is also plausible, although it usually implies an *action* (issue/split). Given the context of mandatory disclosure of the total share count, RNS is the safest general regulatory classification.
2019-04-08 French
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is a press release announcing that Genomic Vision has signed a financing contract with Winance for an equity refinancing of €5 million, structured in tranches with attached warrants (ABSAs). This clearly details a fundraising and capital structure change activity. Based on the definitions, this aligns perfectly with the 'Capital/Financing Update' category (Code: CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Since it is a detailed announcement of the financing terms, it is classified as CAP rather than a general Regulatory Filing (RNS). The document length (8345 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2019-03-26 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that Genomic Vision has signed a financing agreement with Winance for a total amount of 5 M€, structured in 4 tranches through the issuance of shares with attached warrants (ABSA). This directly relates to the company raising capital or changing its financing structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA), as it contains the substantive details of the financing deal itself.
2019-03-26 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.